In a year in which he faced down a challenge from an activist investor, Pfizer CEO Albert Bourla, Ph.D., received a 14% total ...

Pfizer has terminated a Phase I trial of its investigational STING therapy in advanced solid tumors, according to an update ...

Over the past six decades, hundreds of millions of people have taken Xanax or one of its relatives in the benzodiazepine family for a range of ...

The most recent trading session ended with Pfizer (PFE) standing at $25.60, reflecting a -0.43% shift from the previouse trading day's closing. This change was narrower than the S&P 500's daily loss ...

This article has been corrected to reflect that the senators asked UpScriptHealth to respond. In August 2024, Pfizer Inc ...

Guggenheim analyst Vamil Divan maintained a Buy rating on Pfizer (PFE – Research Report) yesterday. The company’s shares closed yesterday at ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

LM Real Estate Partners of New York sold Lightstone the property — the firm paid $9 million for it in 2019. The combined ...

Representative Jefferson Shreve (R-Indiana) recently bought shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on March ...

Shares of Pfizer Inc. PFE slid 2.44% to $25.99 Tuesday, on what proved to be an all-around poor trading session for the stock ...

Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is ...

Pfizer (NYSE:PFE) stock and Arvinas (NASDAQ:ARVN) stock slip in reaction to mixed Phase 3 data for their breast cancer drug ...